Mar 06th 2018

CEPI partners with Themis to advance vaccines against Lassa fever and MERS

Feb 26th 2018

Themis establishes Scientific Advisory Board of experts in virology and vaccine development

More news



Wellington Partners
Life Sciences

A leading European Venture Capital firm investing in early- and growth-stage Life Science companies.



Therapeutics, Medtech, Diagnostics, Digital Health and Biotechnology.

Strong entrepreneurial teams, deep domain knowledge.

Disruptive, innovative tech addressing high unmet medical needs in large markets.



Europe, special circumstances US, leader in Germany.

Seed to late-stage, private companies most of the time.

Ticket sizes from €1m up to €10m over life of investment.



Managing and investing out of funds WP III and WP IV.

More than €200m AUM dedicated to Life Sciences.

Investment Team with strong clinical, scientific and operational backgrounds.